Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.
| Autor: | M Qunies A; Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.; Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA., A Emmitte K; Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Pharmaceutical patent analyst [Pharm Pat Anal] 2022 Mar; Vol. 11 (2), pp. 45-56. Date of Electronic Publication: 2022 Apr 04. |
| DOI: | 10.4155/ppa-2022-0002 |
| Abstrakt: | Slack channels are sodium-activated potassium channels that are encoded by the KCNT1 gene. Several KCNT1 gain of function mutations have been linked to malignant migrating partial seizures of infancy. Quinidine is an anti-arrhythmic drug that functions as a moderately potent inhibitor of Slack channels; however, quinidine use is limited by its poor selectivity, safety and pharmacokinetic profile. Slack channels represent an interesting target for developing novel therapeutics for the treatment of malignant migrating partial seizures of infancy and other childhood epilepsies; thus, ongoing efforts are directed toward the discovery of small-molecules that inhibit Slack currents. This review summarizes patent applications published in 2020-2021 that describe the discovery of novel small-molecule Slack inhibitors. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|